ChinaXiv Reports Clinical Remission of a Critically Ill COVID-19 Patient Treated by Human Umbilical Cord Mesenchymal Stem Cells
The COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies.
ChinaXiv has performed a recent study that has proven significant improvement of a critically ill COVID-19 patient that was treated with the transfer of human umbilical cord mesenchymal stem cells. Celltex is continuing to monitor and participate in this effective research.
If you currently have your MSCs banked at Celltex and are wondering what options are available to you, please contact the Client Services team today by completing the form on our Request a Consultation page, by calling (713) 590-1000 or sending an email to email@example.com. If you are not a client but would like to bank your MSCs, please complete our online client assessment and a Client Services Coordinator will contact you.
More Recent News
Celltex Therapeutics Receives Another FDA Approval: Phase II Clinical Trial Using Mesenchymal Stem Cells (MSCs) as a Prophylactic Against COVID-19Read More
Rick Perry Discusses Celltex’s COVID-19 Clinical Trials on Fox News TV
Former U.S. Secretary of Energy and former Governor of Texas, Rick Perry, was on Fox News TV discussing Celltex’s COVID-19 ongoing clinical trials and the ingenuity that will deliver a victory over this virus.Read More